Navigation Links
Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease
Date:7/3/2008

www.medivation.com" target="_new">http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding anticipated clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Furthermore, as is typically the case at this stage of the regulatory review process, the FDA has not yet performed an in-depth review of Medivation's preclinical and clinical data, so its views remain subject to change. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2007 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, include information about additional factors that could affect the Company's financial and operating results.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... -- Columbia Laboratories, Inc. (Nasdaq: CBRX ) (" ... pharmaceutical company focused on pharmaceuticals for women,s health, today ... ROTH Conference, which will take place from March 8-11 ... Point, California . Management,s presentation will take place ... (12:00 p.m. Eastern Time) in the Promenade room. ...
(Date:3/3/2015)... 3, 2015 /CNW/ - Sante Medical Hair Restoration is ... hair transplantation. The ARTAS Robotic System ... effectively extracts hair for transplantation. This latest development ... results, with no linear scar. "The ... of hair restoration surgery." says Dr. Louis ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... of the "Telemedicine and Mobile Healthcare Solutions, ... - 2020" report to their offering. ... are all terms that pertain to the use ... provide remote clinical/non-clinical healthcare services. They form the ...
Breaking Medicine Technology:No linear scar. Permanent results. 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3
... ANTONIO, April 17, 2012  Mission Pharmacal announced today ... technology licensing agreement with EffRx Pharmaceuticals SA, Freienbach, ... (alendronate sodium) Effervescent Tablets in the ... Drug Administration recently approved BINOSTO to treat osteoporosis ...
... SPRING, Md., April 16, 2012     Sunpeaks Ventures, Inc. ... Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, ... be an official exhibitor at the Thrombosis and Hemostasis ... May 3-5, 2012 at the Hyatt Regency Chicago.  ...
Cached Medicine Technology:Mission Pharmacal and EffRx Bring New Osteoporosis Medication to the United States and Canada 2Mission Pharmacal and EffRx Bring New Osteoporosis Medication to the United States and Canada 3Mission Pharmacal and EffRx Bring New Osteoporosis Medication to the United States and Canada 4Sunpeaks Ventures to Exhibit Clotamin at the first-ever Thrombosis and Hemostasis Summit of North America 2
(Date:3/3/2015)... Dan E. Chambers, an experienced Los Angeles criminal ... recently spoke on the radio to give his insights into ... Independent Journal Review radio show “The Right Mics” chose Chambers ... and now as a criminal defense attorney would provide him ... and sentencing of this high-profile case. , During the ...
(Date:3/3/2015)... The report “Alopecia – Pipeline Review, ... for Alopecia. Alopecia is the loss of hair. Alopecia ... of alopecia. Causes for alopecia include aging, genetics, illness, ... include male pattern hair loss, female diffuse hair loss, ... classified as focal or diffuse and by the presence ...
(Date:3/3/2015)... The first week of March is Sleep ... event brings recognition to a rarely discussed problem that ... to the Centers for Disease Control , 70 million ... another. Too little or unrestful sleep is associated with ... depression, and even a higher likelihood of obesity. ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 The ... better predict antidepressant treatment outcomes for patients with ... than any of the individual genes that comprise ... investigators from the Mayo Clinic and Assurex Health, ... , The proprietary technology of the GeneSight ...
(Date:3/3/2015)... 03, 2015 The North ... to grow from $1,224.6 million to $1,694.6 ... 2014 and 2019. , Browse through the ... market for an analysis of industry trends ... tables and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , ...
Breaking Medicine News(10 mins):Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 2Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 2Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 4Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 6Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3
... who will respond best to interferon beta treatments , ... explain why some multiple sclerosis (MS) patients respond to ... Starting with 206 southern European patients with relapsing-remitting MS, ... compared the DNA of patients whose symptoms were reduced ...
... largest comparison of blood samples collected from healthy individuals ... common Toxoplasma gondii parasite, carried by cats and farm ... report on the study, conducted among U.S. military personnel ... and Johns Hopkins Childrens Center appears in the January ...
... wetlands of southeast Chicago are still being exposed to ... research team reports. The chemicals do not appear to ... findings appear in the current issue of the Journal ... biosciences scientist Jeff Levengood led the study. Levengood, a ...
... Websites with a Turn-Key Solution for Health Portal ... ... Jan. 16 HealthCare.com,( http://www.healthcare.com ), the leading healthcare provider directory ... MediResource ( http://www.mediresource.com ), a leading creator and,syndicator of interactive health ...
... (TSX:,DAX) (NASDAQ: DRAX ) has received approval from ... Course Issuer Bid (NCIB) to,purchase up to 4,072,054 common ... in the public float as at January 14, 2008.,As ... were issued and,outstanding., Purchases may begin on January ...
... Will Analyze Campaign Speeches and Ads During,Presidential Symposium ... 16 Just prior to the primary,elections in ... and clinician Drew Westen, Ph.D., will describe the,emotional ... the Presidential,Symposium of the American Psychoanalytic Association,s 2008 ...
Cached Medicine News:Health News:DNA Analysis Could Help Customize Treatments for MS 2Health News:Toxoplasma infection increases risk of schizophrenia, study suggests 2Health News:Herons persist in Chicago wetlands despite exposure to banned chemicals 2Health News:Herons persist in Chicago wetlands despite exposure to banned chemicals 3Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 2Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 3Health News:DRAXIS Share Buyback Approved by TSX 2Health News:DRAXIS Share Buyback Approved by TSX 3Health News:DRAXIS Share Buyback Approved by TSX 4Health News:2008 Presidential Campaign on the Couch 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: